Abstract
4090Background: TheRADIANT-4 study met its primary end point with a median progression-free survival (PFS) of 11.0 months (mo) for EVE vs 3.9 mo for placebo (PBO; HR = 0.48 [95% CI 0.35-0.67]; P < ...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
